Fulcrum Therapeutics Inc

NASDAQ:FULC   3:59:54 PM EDT
7.29
-0.02 (-0.27%)
Regulatory, Other Pre-Announcement

Fulcrum Therapeutics Announces Results From Redux4 Trial With Losmapimod In Facioscapulohumeral Muscular Dystrophy

Published: 06/24/2021 11:34 GMT
Fulcrum Therapeutics Inc (FULC) - Fulcrum Therapeutics Announces Results From Redux4 Trial With Losmapimod in Facioscapulohumeral Muscular Dystrophy (fshd) Demonstrating Slowed Disease Progression and Improved Function.
Fulcrum Therapeutics Inc - Primary Endpoint, Change in Dux4-driven Gene Expression Which Was Included As an Experimental Biomarker, Was Not Met.
Fulcrum - Losmapimod Showed Statistically Significant & Clinically Relevant Benefit Across Multiple Structural, Functional, Patient Reported Endpoints.
Fulcrum Therapeutics - Losmapimod Was Well Tolerated With No Treatment Related Discontinuations Or Treatment Related Serious Adverse Events.
Fulcrum Therapeutics Inc - Expects to Engage With Health Authorities, Including FDA, in H2 2021.
Fulcrum Therapeutics - Positive Benefit/risk Supports Losmapimod's Potential to Be a Transformative Therapy for Treatment of Fshd.
Fulcrum - Changes in Dux4-driven Gene Expression Could Not Be Demonstrated, Co Believes Due to Several Technical and Biologic Variables With Endpoint.